The lipophilic yeast Malassezia is an exacerbating factor in atopic dermatitis (AD) and colonizes the skin surface of patients with AD. With the goal of reducing the number of Malassezia cells, we investigated the antifungal activities of a therapeutic agent for AD, tacrolimus, and the azole agents itraconazole and ketoconazole against Malassezia species in vitro. We examined 125 strains of the 11 currently accepted Malassezia species by using the agar dilution method. All strains of the 11 Malassezia species were very susceptible to both azole agents, with MICs ranging from 0.016 to 0.25 g/ml. Tacrolimus had antifungal activities against half of the strains, with MICs ranging from 16 to 32 g/ml. Two of the major cutaneous floras, Malassezia globosa and Malassezia restricta, have several genotypes in the intergenic spacer region of the rRNA gene; the azole agents had slightly higher MICs for specific genotype strains of both microorganisms. A combination of azole agents and tacrolimus had a synergistic effect against Malassezia isolates, based on a fractional inhibitory index of 0.245 to 0.378. Our results provide the basis for testing these agents in future clinical trials to reduce the number of Malassezia cells colonizing the skin surface in patients with AD.
Although lipophilic yeasts, Malassezia spp., colonize the skin surface of healthy individuals, they may also cause seborrheic dermatitis (SD), pityriasis (tinea) versicolor, and Malassezia folliculitis and may exacerbate atopic dermatitis (AD) (1) . AD is a common chronic inflammatory skin disease. The standard treatment of AD is topical corticosteroids and topical immunomodulating agents, although some patients do not respond to these treatments. Cutaneous microorganisms are considered an exacerbating factor. Although large numbers of lipophilic Malassezia species organisms colonize the skin surfaces of both AD patients and healthy subjects, anti-Malassezia-specific immunoglobulin E antibody is detected only in AD patient sera (14, 16, 32) . This is probably owing to the disrupted barrier function of the skin surface and the effects of scratching on sensitization to the organisms (30) . The application of topical antifungal agents to AD patients decreases Malassezia colonization and the severity of eczematous lesions (2) , suggesting that Malassezia species play a role in atopic dermatitis. In addition, several candidate Malassezia antigens have been implicated in the pathogenesis of AD (15, 19, 20, 23, 34) .
In 1996, the taxonomy of the genus Malassezia was revised by Guého et al. (8) . The authors described seven species (Malassezia furfur, M. globosa, M. obtusa, M. restricta, M. slooffiae, M. sympodialis, and M. pachydermatis). Subsequently, Japanese researchers found another four new species: Malassezia dermatis (25) , M. yamatoensis (28) , M. japonica (27) , and M. nana (11) were isolated from an AD patient, SD patients, a healthy individual, and an animal, respectively, between 2002 and 2004. At present, 11 species have been accepted in this genus. By use of the revised taxonomy, the correlation between cutaneous Malassezia floras and each skin disease has been investigated. Sugita et al. (24) identified the major Malassezia floras as M. globosa and M. restricta by using a PCR-based nonculture method. In addition, M. globosa and M. restricta consisted of four and two strains with different genotypes, respectively (26, 29) . In the former species, two of the four genotypes were isolates from AD patients, one was from healthy subjects, and the remaining genotype included strains from both AD patients and healthy subjects. In the latter species, one genotype was an isolate from a healthy subject, and the other included isolates from both AD patients and healthy subjects. In this study, we investigated three items: the in vitro susceptibilities of all 11 currently accepted Malassezia species to an immunomodulating agent (tacrolimus) and two antifungal agents (itraconazole [ITC] and ketoconazole [KTZ]), their in vitro susceptibilities to a combination of tacrolimus and an azole agent, and the in vitro susceptibilities of the strains of M. globosa and M. restricta with each genotype to these three agents.
MATERIALS AND METHODS
Malassezia isolates. We examined 125 strains of 11 Malassezia species for their in vitro drug susceptibilities to tacrolimus and azole agents (ITC and KTZ), as shown in Table 1 . The Malassezia strains were isolated mainly from AD outpatients and healthy volunteers. Animal isolates of M. nana and M. pachydermatis were provided by R. Kano of Nihon University and K. Takeo of Chiba University, respectively. OpSite transparent dressings (3 by 7 cm; Smith and Nephew Medical Ltd., Hull, United Kingdom) were applied to the scalp, back, arm, and nape of the neck of each subject. The samples were then transferred onto modified Leeming and Notman agar (mLNA) (10 g glucose, 10 g peptone, 8 g bile salts [OXOID, Hampshire, United Kingdom], 2 g yeast extract, 0.5 g glycerol monostearate, 15 g agar, 10 ml glycerol, 5 ml Tween 60, and 20 ml olive oil) containing 50 g of chloramphenicol (Sankyo, Tokyo, Japan) and incubated at 32°C until yeast colonies were recovered. All 125 Malassezia isolates were identified by using rRNA gene sequence analysis. The isolated microorganisms were maintained on mLNA medium at 32°C.
Drugs. ITC and KTZ were kindly supplied by Janssen Pharmaceutical Company (Tokyo, Japan) and were diluted in dimethyl sulfoxide (Wako Chemical, Osaka, Japan). Stock solution was stored at Ϫ20°C until use. The injectable tacrolimus solution was purchased from Fujisawa Pharmaceutical Company (Osaka, Japan).
Drug susceptibility testing. In vitro drug susceptibility was determined according to the method of Gupta et al. (9), with slight modification. Briefly, the drugs were diluted in 200 l of mLNA broth, to make a dilution series with doubled concentrations ranging from 0.16 to 320 g/ml. To each diluted drug concentration, 1,800 l of melted mLNA medium was added, resulting in final concentrations ranging from 0.016 to 32 g/ml. The surface of each agar plate was inoculated with 50 l of cell suspension and incubated for 7 days at 32°C. The cell growth was compared with the growth in a drug-free control, according to the following scale: 0, no visible yeast colonies on the agar medium; 1ϩ, 25% growth in comparison with control; 2ϩ, 50% of control growth; 3ϩ, 75% of control growth; and 4ϩ, growth similar to that of the control (9) . MIC testing was carried out at least three times.
Synergy testing. The interactions of tacrolimus and the azole agents were estimated by antimicrobial susceptibility testing on mLNA agar medium, to test for synergy between these agents. 
RESULTS
In vitro susceptibility to tacrolimus and azole agents. The MICs of the three drugs are shown in Tables 2, 3 , and 4. All the Malassezia species were very susceptible to both ITC and KTZ, with MICs ranging from 0.016 to 0.25 g/ml, and approximately 80% of the strains had an MIC of Յ0.03 g/ml. Tacrolimus had an antifungal effect against approximately 50% of the Malassezia strains, with MICs ranging from 16 to 32 g/ml. This agent did not have an antifungal effect against the remaining 50% of the strains. In vitro susceptibility testing using a combination of the azole agents and tacrolimus was conducted using the six isolates of M. furfur, M. globosa, M. restricta, and M. sympodialis that had an MIC of ITC or KTZ of Ͼ0.125 g/ml. When ITC or KTZ was combined with tacrolimus, the MICs against these isolates were reduced (Tables  5 and 6 ). The FIX of all these isolates were below 0.5 (synergistic effect).
In vitro susceptibilities of the strains of M. globosa and M. restricta with each genotype. Previously, we demonstrated that M. globosa and M. restricta organisms colonizing the skin surface of AD patients and healthy individuals were divided into four and two genotypes, respectively, by using the intergenic spacer region of the rRNA gene ( Fig. 1 and 2 ; Table 1 ). For M. globosa, genotypes I and II are strains isolated from AD patients, genotype III contains strains obtained from both AD patients and healthy subjects, and genotype IV consists of strains isolated from healthy individuals only. The MICs of ITC and KTZ for this microorganism ranged from 0.016 to 0.25 g/ml and from 0.016 to 0.125 g/ml, respectively (Tables  2 and 3 ). All the strains with MICs of ITC and KTZ greater than 0.125 g/ml belonged to genotype I. The MICs of ITC and KTZ for the genotype I strains were higher than those for the other genotype strains. For the tacrolimus MIC, no remarkable differences were found between the genotype strains (Table 4 ). For M. restricta, genotype I includes only strains isolated from AD patients, while genotype II includes strains obtained from both AD patients and healthy individuals. The MICs of ITC and KTZ for genotype I strains were higher than those for genotype II strains (Tables 2 and 3 ). For the tacrolimus MIC, no remarkable difference between the strains of each genotype was found (Table 4) .
DISCUSSION
This study describes in vitro susceptibility testing of the 11 currently recognized Malassezia species to ITC, KTZ, and tacrolimus, and combined azole agent and tacrolimus. All 11 Malassezia species were very susceptible to both ITC and KTZ. These results are consistent with those documented in the literature (7, 9, 22 ). Within the very-susceptible range, how- M. obtusa 88.9 (7) 11.1 (1)
M. nana 100 (4)
M. dermatis 100 (3) M. japonica 100 (2) M. yamatoensis 100 (2) M. pachydermatis 100 (6) a Numbers of strains examined are shown in parentheses.
ever, variations in the susceptibilities of the major cutaneous floras M. globosa and M. restricta and the minor floras M. sympodialis and M. furfur to both agents was observed, with MICs ranging from 0.016 to 0.25 g/ml. While the MIC of voriconazole for Malassezia species is similar to that of ITC and KTZ, that of fluconazole is greater than that of ITC and KTZ (9) . In contrast to the azole agents, the variation in susceptibility to terbinafine is greater than that for the azole agents. Gupta et al. (9) M. restricta to ITC and KTZ were correlated. Although a limited number of strains was examined, genotype I strains, which were obtained from AD patients only, had higher MICs for ITC and KTZ than did the strains with other genotypes. The reason for the correlation between genotype and susceptibility to ITC and KTZ is unclear. If an AD patient is given antifungal drugs repeatedly, the drug susceptibility of the fungi colonizing the patient's skin will change, but as no patient in this study received antifungal therapy, this possibility can be excluded. The cutaneous lipid composition in AD patients is slightly different from that of healthy subjects (10, 33) . Such differences in composition may affect colonization by strains with different lipid requirements. In addition, the base ingredients in topical ointments affect the growth of Malassezia species (13) . Of course, these factors do not affect drug susceptibility directly, but they do affect the selective colonization of microorganisms and might have an incidental effect that results in differences in drug susceptibility. Clinical trials using ITC and KTZ in AD treatment have been conducted, and several studies have shown that these drugs are clinically effective in treating AD. AD patients with a positive radioallergosorbent test for Malassezia, who were treated with oral KTZ (200 mg/day for 2 months and 200 mg twice a week for another 3 months), had improved clinical scores for AD severity, particularly for the head and neck area (18) . Oral ITC also improved the AD severity in patients with positive intradermal reactions to Malassezia and reduced the Malassezia radioallergosorbent test value (18) . These investigations imply that ITC and KTZ therapies offer a promising treatment option for AD patients who are refractory to usual treatments. However, the optimal dosing regimens and treatment duration in larger clinical trials should be determined.
Tacrolimus, a therapeutic agent for AD treatment, also has an antifungal effect against approximately half of the Malassezia strains. The immunosuppressive drugs cyclosporine and tacrolimus target calcineurin, and these agents are toxic to Candida albicans and Cryptococcus neoformans (4) . In addition, we demonstrated that tacrolimus, with either ITC or KTZ, has synergistic activity against Malassezia. These observations follow earlier reports on a combination of tacrolimus and fluconazole against C. albicans and C. neoformans strains. As immunosuppressive agents cannot be given to patients with deep-seated mycosis (immunocompromised hosts), the nonimmunosuppressive analog L-685,818 has been synthesized (5). The combination of topical tacrolimus and an azole agent can simultaneously treat AD and reduce the number of Malassezia cells colonizing the skin surface that are an exacerbating factor. While the synergistic mechanism of the combination of tacrolimus and azole agents is not known, Maesaki et al. (17) demonstrated that tacrolimus increases the intracellular concentration of the azole agent in their study of C. albicans. We found no ITC-or KTZ-resistant Malassezia strains. When azole-resistant Malassezia strains colonize the skin, combined treatment with tacrolimus can render them susceptible to azole agents.
FIG. 1. Molecular phylogenetic tree of the M. globosa isolates. A tree was constructed from IGS1 sequences of the rRNA gene by using a neighbor-joining analysis (21) after the sequences were aligned by using ClustalW (31) . The distances between sequences were calculated by using Kimura's two-parameter model (12) . The numbers indicate the confidence levels from 100 replicate bootstrap samplings (frequencies less than 50% are not shown) (6) . HS, healthy subject. Knuc, Kimura's parameter (12).
FIG. 2. Molecular phylogenetic tree of M. restricta isolates. The tree was constructed using the method described in the legend for Fig.  1 . HS, healthy subject. Knuc, Kimura's parameter (12). 
